Domino's Pizza, Inc. (DPZ) Stock Price Today
Aura AI Summary
Key Stats
- $11.32BMarket Cap
- -Volume
- Consumer CyclicalSector
- $467.3052W High
- $282.8952W Low
- -Typical Hold Time
- $16.27BEnterprise Value
- 2.33%Div Yield
- -Trading Activity
Track Domino's Pizza, Inc. (DPZ) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Domino's Pizza, Inc. has traded between a low of $282.89 and a high of $467.3, highlighting its annual price range. Buy and sell Domino's Pizza, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Most Recent News
Alumis stock plunges 57% after lupus drug trial fails, but psoriasis drug progress continues.
Alumis' stock dropped 56.58% after its Phase II lupus drug trial failed to meet main goals, causing a significant market reaction. However, positive results in a subgroup of lupus patients with a high interferon gene signature offer a potential path ...

SPACs, biotech, geothermal, and AI stocks rally with major deals and volatility driving gains
SPAC stocks like Rising Dragon Acquisition surged nearly 47% amid volatility, while biotech firm bioAffinity Technologies jumped 44% after a reverse stock split. Renewable energy company Fervo Energy gained 28% following a major geothermal power deal...

Alumis plunges 57% after trial failure; Enovis falls 16% on robotics acquisition news
Alumis Inc. shares dropped 56.76% after its Phase 2b trial for a lupus drug failed to meet key goals, though some patient groups showed promise. Enovis Corporation shares fell 16.51% following its announcement to acquire eCential Robotics for €155 mi...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.